Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors
Protein Kinase Inhibitors
Receptor, Epidermal Growth Factor
Approximately 40% of human glioblastomas harbor oncogenic EGFR alterations, but attempts to therapeutically target EGFR with first-generation EGFR kinase inhibitors have failed. Here, we demonstrate selective sensitivity of glioma-specific EGFR mutants to ATP-site competitive EGFR kinase inhibitors that target the inactive conformation of the catalytic domain.